Vertex Pharmaceuticals Inc (VRTX) stock
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3030% above fair value
$537.79−0.81 (-0.15%)
Close on Nov 16, 2026Market cap $136.31BP/E 31.3Yield –
Vertex Pharmaceuticals price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Vertex Pharmaceuticals's price to sales ratio was 11.0× on Nov 11, 2026, against 9.4× a year earlier. Over the last 5 years it ranged from 7.7× to 12.6×, with a median of 9.8×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 11.0× | +1.2 |
| 2025 | Dec 31, 2025 | 9.8× | +0.1 |
| 2024 | Dec 31, 2024 | 9.8× | −1.1 |
| 2023 | Dec 29, 2023 | 10.9× | +2.3 |
| 2022 | Dec 30, 2022 | 8.5× | +0.6 |
| 2021 | Dec 31, 2021 | 7.9× | −2.4 |
| 2020 | Dec 31, 2020 | 10.3× | −5.3 |
| 2019 | Dec 31, 2019 | 15.6× | +0.6 |
| 2018 | Dec 31, 2018 | 15.0× | −1.5 |
| 2017 | Dec 29, 2017 | 16.5× | +5.5 |
| 2016 | Dec 30, 2016 | 11.0× | −29.7 |
| 2015 | Dec 31, 2015 | 40.7× | +4.5 |
| 2014 | Dec 31, 2014 | 36.3× | +21.7 |
| 2013 | Dec 31, 2013 | 14.5× | +9.4 |
| 2012 | Dec 31, 2012 | 5.2× | −2.4 |
| 2011 | Dec 30, 2011 | 7.6× | −56.1 |
| 2010 | Dec 31, 2010 | 63.7× | +29.4 |
| 2009 | Dec 31, 2009 | 34.3× | – |
See a number that looks wrong?